Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.
biomarker
bladder cancer
cystectomy
digital pathology
immunoscore
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
received:
11
04
2022
revised:
20
05
2022
accepted:
29
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
To evaluate the prognostic value of a modified Immunoscore (mIS) in a cohort of bladder cancer (BC) patients undergoing radical cystectomy (RC), two tissue microarrays of 159 BC patients were immunohistochemically stained for CD3/CD8/FOXP3 and CD45RO to detect Tumor-Infiltrating Lymphocytes (TIL). To predict progression free survival (PFS) and cancer specific survival (CSS), a predictive model cumulatively incorporating all four components was constructed and labeled as mIS. Patients were stratified into two risk groups; "high mIS/favorable risk" and "low mIS/unfavorable risk". Kaplan-Meier analysis was used to test mIS within each American Joint Committee on Cancer (AJCC) stage group for BC. In a univariable cox regression analysis all single components used for mIS, showed a significant association with CSS. Patients with high mIS (all components) in the AJCC stage IIIa group additionally showed a significantly longer PFS (Hazard Ratio (HR): 2.7;
Identifiants
pubmed: 35741170
pii: diagnostics12061360
doi: 10.3390/diagnostics12061360
pmc: PMC9222135
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ecancermedicalscience. 2014 Dec 01;8:486
pubmed: 25525464
J Clin Oncol. 2009 Jan 10;27(2):186-92
pubmed: 19064967
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72
pubmed: 17360461
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Urol Oncol. 2021 Feb;39(2):131.e17-131.e21
pubmed: 32773233
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
J Immunother Cancer. 2017 Aug 15;5(1):68
pubmed: 28807024
Urol Oncol. 2022 Mar;40(3):108.e19-108.e25
pubmed: 34903453
Nat Rev Urol. 2014 Mar;11(3):153-62
pubmed: 24492433
Histopathology. 2018 Aug;73(2):327-338
pubmed: 29575153
J Urol. 2006 Mar;175(3 Pt 1):881-5
pubmed: 16469571
Int J Biol Markers. 2020 Sep;35(3):3-13
pubmed: 32538254
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Eur Urol. 2013 Jan;63(1):4-15
pubmed: 23083902
Am J Pathol. 2020 Sep;190(9):1960-1970
pubmed: 32585158
Nat Rev Urol. 2016 Aug;13(8):471-9
pubmed: 27431340
PLoS One. 2018 Oct 11;13(10):e0205746
pubmed: 30308033
J Immunol. 2017 Feb 1;198(3):981-985
pubmed: 28115586
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Nat Rev Urol. 2019 Sep;16(9):507
pubmed: 31388107
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cancer Res. 2013 Feb 1;73(3):1097-106
pubmed: 23243026
BJU Int. 2011 Nov;108(10):1672-8
pubmed: 21244603
World J Urol. 2016 Feb;34(2):181-7
pubmed: 26055646
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Cell Int. 2020 Jul 11;20:302
pubmed: 32675942
J Clin Pathol. 2021 Feb;74(2):102-105
pubmed: 32527754